Issue 6/2012

  • Obama’s new biobased economy

    In this issue:

    • Cover Story: Obama’s new biobased economy - The bioeconomy begins to go truly global
    • GSK absorbs Cellzome; German biotech sector expanding
    • Abbott buys kidney treatment from Action Pharma
    • DSM enters biomedicine with takeover of Kensey Nash
    • SPECIAL: BiobasedWorld at Achema – The guide to the trade fair
    • Zeltia pockets Yondelis milestone from Johnson & Johnson
    • Selvita stuffs its war-chest with shares, grants and awards
    • Pattern of DNA methylation determines genome stability

Volume 2016

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/6/pos/1.html?sort=desc&cHash=8305edff5982cb307c5ea48106acb36a

Kurszettel

Alle Kurse

TOP

  • MOLOGEN (D)1.75 EUR16.67%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%
  • RENEURON (UK)3.15 GBP5.00%

FLOP

  • VECTURA (UK)148.80 GBP-4.25%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • BONE THERAPEUTICS SA (B)16.05 EUR-3.31%

TOP

  • PROTHENA PLC (IE)52.22 USD47.2%
  • FLAMEL TECHNOLOGIES (F)12.58 USD33.1%
  • DBV TECHNOLOGIES (F)64.40 EUR26.3%

FLOP

  • MOLOGEN (D)1.75 EUR-30.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.62 GBP-19.5%

TOP

  • KARO BIO (S)29.80 SEK1774.2%
  • NICOX (F)11.20 EUR474.4%
  • SAREUM HOLDINGS (UK)0.62 GBP158.3%

FLOP

  • BB BIOTECH (D)45.00 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.72 SEK-78.9%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 25.07.2016